Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab for induction of remission in Crohn's Disease
NCT00055523Phase 2Completed
- Sponsor
- Abbott Laboratories
- Start
- Apr 2002
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of adalimumab in Crohn's disease (4 arms), sponsored by Abbott Laboratories. Primary endpoint: Induction of Clinical Remission at 4 weeks. Started Apr 2002; status: completed.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00055523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00055523.